Pancreatic Cancer Research

ResearcherUniversity of AlabamaActive in the last 2 years

John Bart Rose

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0471-3978; OpenAlex author ID A5046990205, A5121179983. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
86
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers · 2025: 5 papers · 2026: 3 papers

Papers 23

  1. Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-026-12810-2↗
  2. Intersection of race and poverty for pancreatic adenocarcinoma: A public health crisis. Co-author DOI 10.1016/j.amjsurg.2025.116707↗
  3. Racial Disparities in Chemotherapy Response in Pancreatic Cancer: A Landmark Survival Analysis. Co-author DOI 10.1016/j.jss.2025.11.051↗
  4. Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review. Co-author DOI 10.1016/j.ejca.2025.115384↗
  5. Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis. Co-author DOI 10.1016/j.jss.2025.04.042↗
  6. Corrigendum to 'Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-analysis' Jou… Co-author DOI 10.1016/j.jss.2025.10.015↗
  7. Impact of electronic patient-reported outcomes (ePRO) presentation in pancreatic cancer tumor board discussions on cancer outcomes: the INSPIRE intervention. Co-author DOI 10.1186/s12885-025-14847-w↗
  8. Bibliometric review of journal articles on pancreatic cancer: insights into productivity and impact. Co-author DOI 10.21037/apc-24-22↗
  9. Exploring Disparities in Pancreatic Ductal Adenocarcinoma Outcomes among Asian and Pacific Islander Subgroups. Co-author DOI 10.1158/2767-9764.crc-24-0177↗
  10. An Analysis on the Effect of Income Changes in the Resection of Early-Stage Pancreatic Adenocarcinoma. First author DOI 10.1177/00031348241256058↗
  11. Implementation of ePROs Into Multidisciplinary Tumor Board Discussions for Patients With Pancreatic Cancer: The INSPIRE Intervention. Co-author DOI 10.6004/jnccn.2024.7052↗
  12. Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer? Co-author DOI 10.1016/j.jss.2022.11.031↗
  13. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  14. Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.amjsurg.2022.04.004↗
  15. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
  16. The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy. First author DOI 10.1097/mpa.0000000000001972↗
  17. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Co-author DOI 10.1634/theoncologist.2019-0878↗
  18. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2020.00620↗
  19. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
  20. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. First author DOI 10.1002/jso.25498↗
  21. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Poi… Co-author DOI 10.1097/rli.0000000000000505↗
  22. Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer. Co-author DOI 10.1245/s10434-013-3431-6↗
  23. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Co-author DOI 10.1245/s10434-014-3486-z↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vikas Dudeja · 7 shared papers, 2022–2025 · strength 1.44
  2. Andrea Gillis · 5 shared papers, 2024–2026 · strength 1.39
  3. Sushanth Reddy · 6 shared papers, 2022–2025 · strength 1.27
  4. Christopher Wu · 4 shared papers, 2024–2026 · strength 1.07
  5. K Kerrick Akinola · 3 shared papers, 2025–2026 · strength 0.88
  6. Michelle M. Holland · 3 shared papers, 2025–2026 · strength 0.85
  7. Ahmer Irfan · 4 shared papers, 2022–2024 · strength 0.78
  8. Annabelle L. Fonseca · 2 shared papers, 2025 · strength 0.54
  9. Chandler A. Annesi · 2 shared papers, 2025 · strength 0.54
  10. Martin J. Heslin · 2 shared papers, 2025 · strength 0.54
  11. Júlia Adriana Kasmirski · 2 shared papers, 2025 · strength 0.51
  12. Selwyn Maurice Vickers · 3 shared papers, 2022–2023 · strength 0.50
  13. Olumide B. Gbolahan · 3 shared papers, 2022–2023 · strength 0.50
  14. Gabrielle Betty Rocque · 2 shared papers, 2024–2025 · strength 0.46
  15. Garrett Bourne · 2 shared papers, 2024–2025 · strength 0.46
  16. Nicole L. Henderson · 2 shared papers, 2024–2025 · strength 0.46
  17. Ryan David Nipp · 2 shared papers, 2024–2025 · strength 0.46
  18. Scott W. Helton · 5 shared papers, 2014–2023 · strength 0.41
  19. Harrison Kim · 2 shared papers, 2019–2026 · strength 0.34
  20. Desiree E. Morgan · 2 shared papers, 2019–2026 · strength 0.34
  21. Hua Amanda Fang · 2 shared papers, 2022–2023 · strength 0.32
  22. Adnan A. Alseidi · 4 shared papers, 2014–2020 · strength 0.32
  23. Flavio G. Rocha · 4 shared papers, 2014–2020 · strength 0.32
  24. Seifeldin Awad · 2 shared papers, 2020–2022 · strength 0.29
  25. Martin D. Holland · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.